首页> 外文期刊>Journal of viral hepatitis. >Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance.
【24h】

Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance.

机译:难治性慢性丙型肝炎与干扰素清除相关的干扰素-α治疗前对干扰素-γ引发的免疫反应。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to clarify the immunological and virological responses to pre-administration of interferon-gamma prior to initiation of interferon-alpha treatment in patients with refractory chronic hepatitis C. Twenty-two nonresponders to 6-months of IFN-alpha treatment were enrolled. The hepatitis C virus (HCV) genotype was Ib in all. Natural IFN-gamma (1 MIU/day) was administered daily for 14 days followed by natural IFN-alpha (5 MIU/day) daily for 14 days and then three times weekly for 22 weeks. Serum immunological parameters (IL-10, neopterin, BMG, sCD8, sCD4, IL-6, IL-12) were measured as were the levels of several cytokines (IFN-gamma, TNF-alpha, IL-2, IL-4, IL-5, IL-6, IL-10). Three patients dropped out; two because of the occurrence of other diseases and one because of an adverse effect. At the end of the period of IFN-alpha treatment, HCV-RNA had become negative in six of 19 patients (end-of treatment response; ETR). Six months after the completion of IFN administration, a virological sustained response (SR) was seen in two of 19 patients. The mean serum levels of IL-10 were significantly decreased 6 weeks after the start of treatment. Other immunological parameter levels increased significantly during the period of IFN-gamma administration, and tended to return to the pretreatment level after the start of IFN-alpha administration. Univariate logistic regression analysis showed that the initial change in the levels of these parameters or the change in the ratios of Th1/Th2 parameter levels are useful factors indicative of the end of the treatment response. These findings suggest that priming with IFN-gamma prior to the initiation of IFN-alpha treatment in patients with refractory chronic hepatitis C can modulate the host immune response and this might contribute to viral clearance.
机译:这项研究的目的是阐明难治性慢性丙型肝炎患者在开始使用干扰素-α之前对干扰素-γ的预先给药的免疫学和病毒学反应。IFN-α治疗六个月至二十二个月无反应被录取了。丙型肝炎病毒(HCV)基因型总计为Ib。每天施用天然IFN-γ(1 MIU /天),持续14天,然后每天施用天然IFN-α(5 MIU /天),持续14天,然后每周三次,持续22周。测量血清免疫学参数(IL-10,新蝶呤,BMG,sCD8,sCD4,IL-6,IL-12)以及几种细胞因子(IFN-γ,TNF-α,IL-2,IL-4, IL-5,IL-6,IL-10)。三名患者退学。二是由于其他疾病的发生,一是由于不良影响。在IFN-α治疗期结束时,HCV-RNA在19例患者中有6例变为阴性(治疗结束反应; ETR)。 IFN给药完成六个月后,在19例患者中有2例观察到病毒学持续应答(SR)。治疗开始6周后,平均血清IL-10水平明显降低。在IFN-γ给药期间,其他免疫学参数水平显着提高,并在开始IFN-α给药后趋于回到治疗前水平。单因素逻辑回归分析表明,这些参数水平的初始变化或Th1 / Th2参数水平的比率变化是指示治疗反应结束的有用因素。这些发现表明,在难治性慢性丙型肝炎患者中,在开始IFN-α治疗之前用IFN-γ引发可以调节宿主的免疫反应,这可能有助于病毒清除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号